Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery
A Systematic Review and Meta-analysis

Oluwadotun D. Lawal, MPH; Justin Gold, BS; Amala Murthy, PharmD; Rupam Ruchi, MD; Egle Bavry, MD; Anne L. Hume, PharmD; Adam K. Lewkowitz, MD; Todd Brothers, PharmD; Xuerong Wen, PhD, MPH, MS

Abstract

IMPORTANCE Prolonged opioid use after surgery may be associated with opioid dependency and increased health care use. However, published studies have reported varying estimates of the magnitude of prolonged opioid use and risk factors associated with the transition of patients to long-term opioid use.

OBJECTIVES To evaluate the rate and characteristics of patient-level risk factors associated with increased risk of prolonged use of opioids after surgery.

DATA SOURCES For this systematic review and meta-analysis, a search of MEDLINE, Embase, and Google Scholar from inception to August 30, 2017, was performed, with an updated search performed on June 30, 2019. Key words may include opioid analgesics, general surgery, surgical procedures, persistent opioid use, and postoperative pain.

STUDY SELECTION Of 7534 articles reviewed, 33 studies were included. Studies were included if they involved participants 18 years or older, evaluated opioid use 3 or more months after surgery, and reported the rate and adjusted risk factors associated with prolonged opioid use after surgery.

DATA EXTRACTION AND SYNTHESIS The Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed. Two reviewers independently assessed and extracted the relevant data.

MAIN OUTCOMES AND MEASURES The weighted pooled rate and odds ratios (ORs) of risk factors were calculated using the random-effects model.

RESULTS The 33 studies included 1922 743 individuals, with 1 854 006 (96.4%) from the US. In studies with available sex and age information, participants were mostly female (1 031 399; 82.7%) and had a mean (SD) age of 59.3 (12.8) years. The pooled rate of prolonged opioid use after surgery was 6.7% (95% CI, 4.5%-9.8%) but decreased to 1.2% (95% CI, 0.4%-3.9%) in restricted analyses involving only opioid-naive participants at baseline. The risk factors with the strongest associations with prolonged opioid use included preoperative use of opioids (OR, 5.32; 95% CI, 2.94-9.64) or illicit cocaine (OR, 4.34; 95% CI, 1.50-12.58) and a preoperative diagnosis of back pain (OR, 2.05; 95% CI, 1.63-2.58). No significant differences were observed with various study-level factors, including a comparison of major vs minor surgical procedures (pooled rate: 7.0%; 95% CI, 4.9%-9.9% vs 11.1%; 95% CI, 6.0%-19.4%; P = .20). Across all of our analyses, there was substantial variability because of heterogeneity instead of sampling error.

(continued)
CONCLUSIONS AND RELEVANCE  The findings suggest that prolonged opioid use after surgery may be a substantial burden to public health. It appears that strategies, such as proactively screening for at-risk individuals, should be prioritized.

JAMA Network Open. 2020;3(6):e207367. doi:10.1001/jamanetworkopen.2020.7367

Introduction

The misuse, overdose, and abuse of prescription opioids constitute sources of substantial morbidity and mortality in the US and globally.\(^1\)\(^-\)\(^5\) Approximately 130 individuals in the US die each day of opioid overdose, with one of the largest proportion of preventable deaths in the US being attributable to opioid-related deaths.\(^3\) In addition to the substantial mortality burden, prescription opioid misuse, abuse, dependence, and overdose were reported to cost the US health care system an estimated $78.5 billion in 2013.\(^5\) Increases in prescription opioid use and incidence of opioid-related deaths have also been reported globally, including in European countries and Canada.\(^4\)\(^-\)\(^7\)\(^-\)\(^9\)

Many of the efforts to curb the opioid crisis in the US have focused on regulatory changes regarding opioid use for chronic, noncancer pain, with the guidance for postoperative opioid analgesia use being less clear.\(^10\)\(^-\)\(^12\) The medical literature\(^12\)\(^,\)\(^13\) purports that inappropriate opioid prescribing for peri- and postoperative analgesia in the form of inadequate or excessive dispensing may contribute to the ongoing epidemic. Of note, opioids remain the standard of care for treatment of acute and routine postoperative pain,\(^14\)\(^,\)\(^15\) and surgical procedures remain the primary reason for exposure to these medications.\(^12\)\(^,\)\(^16\) There is also substantial variation in opioid prescribing among clinicians, particularly in the quantities and dosages of opioids after common general surgical procedures.\(^17\)\(^,\)\(^18\) This variation is further complicated with the potential for misuse and diversion, with 67% to 92% of all opioids prescribed for postoperative pain remaining unused.\(^19\)

The association between opioid prescribing after surgery and the opioid crisis is complex. Inadequate postoperative pain management, including using opioids, has been reported to be associated with increased risk for chronic pain, thus warranting the need for long-term opioid use.\(^20\)\(^-\)\(^25\) Conversely, the receipt of prescription opioids after surgery is suggested to be associated with increased risk for chronic opioid use. In a retrospective analysis of population-based claims data from Canada,\(^26\) individuals prescribed opioids within 7 days of a low-risk surgical procedure were 44% more likely to become prolonged opioid users within 1 year after surgery compared with individuals who did not receive these medications. Lastly, undergoing a surgical procedure has been hypothesized as an independent risk factor for prolonged opioid use after surgery.\(^10\)\(^,\)\(^12\)\(^,\)\(^27\)\(^-\)\(^29\)

Although several studies have sought to quantify the rate of and characterize risk factors for prolonged opioid use after surgery, the extent and strength of association have been inconsistent. Despite using similar definitions of prolonged opioid use and eligibility criteria, studies\(^30\)\(^-\)\(^32\) enrolling opioid-naïve patients undergoing major surgical procedures in the US reported incidence rates ranging from 0.5% to 13.0%. Incidence rates as high as 44% for 1 year after surgery have also been reported.\(^33\)\(^,\)\(^34\) To address these conflicting results and to account for potential bias related to differences in study-level factors and low sample sizes, we performed a meta-analysis of published literature to systematically characterize and aggregate the magnitude and patient-level risk factors associated with increased risk of prolonged opioid use after surgery.

Methods

This systematic review and meta-analysis was conducted according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) reporting guidelines.\textsuperscript{35,36} The study protocol is available in the PROSPERO database (CRD42019129239).

**Literature Search**
Relevant studies were identified through an initial literature search of MEDLINE, Embase, and Google Scholar from inception of these databases to August 30, 2017, with an updated search performed on June 30, 2019. Eligible studies were identified from electronic databases using search terms and keywords such as opioid analgesics, general surgery, surgical procedures, persistent opioid use, and postoperative pain. The full search strategy is available in the eAppendix in the Supplement. We also searched bibliographies of relevant articles to identify additional eligible publications.

**Study Selection**
Two of us (J.G. and A.M.) independently assessed all titles and abstracts of studies to determine studies eligible for full-text review. Eligible studies were restricted to published observational studies evaluating opioid use after surgery. Studies were included if they (1) were published in the English language; (2) enrolled participants 18 years or older; (3) included a minimum of 50 patients; (4) involved a noninjectable opioid prescription fill at least 3 months after the index surgical procedure; and (5) reported the rate and adjusted outcome estimates for patient-level risk factors associated with prolonged opioid use after surgery. Given differences with opioid use in cancer vs noncancer pain management, we excluded studies evaluating cancer pain. In addition, eligible studies needed to have accounted for opioids dispensed in the perioperative period or to have incorporated a lag period for at least 1 month after the index surgical procedure. This criterion was included to account for opioids prescribed as part of routine management of postoperative pain before assessing prolonged opioid use after surgery.

Currently, there is not an accepted definition of prolonged opioid use in the medical literature. Therefore, all studies that met the inclusion criteria were considered regardless of variations in the operational definition of prolonged opioid use within and among studies. However, because opioids are often prescribed preemptively to manage peri- or postoperative pain during the few days or months, in some instances, after surgery, we set a 3-month threshold after the index surgical procedure before assessing prolonged opioid use. As such, prolonged opioid use in this study refers to any opioid use pattern reported by the included studies occurring at least 3 months after surgery. An exception is use of the term chronic opioid use. Based on previous literature,\textsuperscript{2,11,37-40} we defined chronic opioid use as the receipt of at least 10 opioid prescription fills, at least 90 consecutive days’ supply of opioids, or 120 cumulative days in the first year after surgery, excluding the initial 90 postoperative days. Because we expected substantial between-study variation in prolonged opioid use definitions, in sensitivity analyses, we repeated our primary analysis to assess the pooled rate of prolonged opioid use by aggregating evidence across studies involving comparable definitions for opioid use after surgery (eTable 1 in the Supplement).

**Data Extraction**
Data extraction was performed by the same 2 reviewers (J.G. and A.M.) from the literature search using structured forms. A third reviewer (O.D.L.) assessed the data extraction forms for completeness and accuracy. Extracted information from eligible studies included the study design, sample size, length of follow-up, types of surgical procedure, proportions of opioid-naive and opioid-experienced individuals at baseline, and the definitions of prolonged opioid use after surgery. In addition, rates and adjusted estimates associated with the longest follow-up time were extracted. We did not contact authors for information missing from published texts.
Quality Assessment

The quality of included studies was assessed by 2 independent reviewers (O.D.L. and J.G.) using the Newcastle-Ottawa Scale,41 and disagreements were resolved by discussion. Studies with a Newcastle-Ottawa Scale score greater than 7 were considered to be high in quality.

Statistical Analysis

The primary outcomes of interest were the pooled rate and magnitude for individual risk factors of prolonged opioid use after surgery. No restrictions were made in the type of effect estimates extracted; therefore, studies reporting odds ratios (ORs), risk ratios, or hazard ratios were eligible for inclusion. Based on the overall low prevalence of the risk factors in the individual studies (ie, <10%), we regarded risk ratios and ORs as equivalent risk measures. However, we pooled studies reporting hazard ratios in a separate analysis. We calculated the pooled rate of prolonged opioid use after surgery weighted by the sample size of each eligible study. When 2 or more studies reported adjusted estimates for the same risk factor, a pooled OR and the corresponding 95% CI were estimated using the inverse variance method with a random-effects model.42 Based on an a priori assumption of substantial between-study variation, we prespecified to use the random-effects model for all meta-analyses. Between-study heterogeneity was tested using the Cochran Q statistic43 and quantified by the $I^2$ value.44 We considered heterogeneity to be significant at $P < .10$ and $I^2 > 50\%$ to indicate substantial between-study variation that was beyond chance.45 Heterogeneity was further assessed in sensitivity analyses. Small-study effect, commonly referred to as publication bias, was examined using a funnel plot and the Egger regression test. Except for heterogeneity, statistical significance was set at $P < .05$; all tests were 2-sided. Statistical analyses were conducted using Comprehensive Meta-Analysis Software, version 3.0 (Biostat).

We performed additional analyses to evaluate the potential sources of heterogeneity and robustness of the primary findings. First, we restricted our analyses to studies enrolling only opioid-naive patients before surgery. We accepted definitions of opioid naive from each eligible study. The definitions of opioid naivety in studies enrolling only opioid-naive participants are presented in eTable 2 in the Supplement. Second, we examined whether the rate of prolonged opioid use after surgery differed by source population or insurance plan, follow-up period (≤6 months vs >6 months), type of surgery (major vs minor surgery and orthopedic vs nonorthopedic surgery), and studies conducted in the US vs non-US countries to assess whether our main finding was moderated by potential differences in prescribing patterns across countries. Classification of major or minor surgery was based on previously published reports11,12,46 and expert opinion (E.B.) (eTable 3 in the Supplement). We then aggregated evidence across studies involving comparable definitions for chronic or prolonged opioid use after surgery. Lastly, for each risk factor reported by at least 3 studies, we recalculated the pooled effect by omitting 1 study at a time. This leave-one-out analysis was performed to determine the influence of an individual study on the pooled effects.

Results

Study Selection

The search of electronic databases yielded 7534 citations. After removal of duplicates and full-text reviews, a total of 33 studies involving 1 922 743 individuals, with 1 854 006 (96.4%) from the US.11,12,16,27,29-33,46-69 The PRISMA diagram is shown in Figure 1.

Study Characteristics

Characteristics of the eligible studies are presented in Table 1. Sample sizes of included studies ranged from 109 to 675 527 participants. The included studies were conducted in Australia, Canada, Denmark, France, the US, and the UK, with 26 (78.8%) from the US. Of the 1 247 216 individuals enrolled in 32 studies with sex information,11,12,16,27,29-33,46-69 1 031 399 (82.7%) were females. Information on age was available in 22 studies11,12,27,29,30,33,38,40,58,60,62-69,46 the mean (SD) age
of participants was 59.3 (12.8) years. The minimum age of participants was 39.0 years and the maximum age was 80.0 years. Of the 33 studies, 14 (42.4%) involved data from commercial insurance plans, 12 (36.4%) used hospital institution data, 5 (15.2%) involved military or veterans’ insurance plans, and the remaining 2 (6.1%) were based on data from national, publicly funded health care systems. Eight studies (24.2%) enrolled only opioid-naive participants, and the remaining 7 studies lacked sufficient information to categorize participants. The definitions of long-term, persistent, and prolonged opioid use and opioid naivety varied across studies (Table 1, and eTables 1-2 in the Supplement). Subgroup analysis based on quality was not performed because the individual summed score from the Newcastle-Ottawa-Scale varied between 7 and 9, suggesting that all included studies were high quality.

**Primary Outcomes**

Across the 33 eligible studies based on random-effects analysis, the pooled rate of prolonged opioid use after surgery was 6.7% (95% CI, 4.5%-9.8%) (Figure 2), with substantial between-study heterogeneity (P < .001; I² = 99.96%).

With the exception of anxiety, we were unable to find comparable risk factors across the 2 studies that used hazard ratios. Therefore, our analyses on risk factors for prolonged opioid use were derived from studies reporting risk ratios or ORs. Significantly increased risks were observed among females compared with males (OR, 1.16; 95% CI, 1.08-1.25) and among individuals with a high school degree vs a college degree or higher (OR, 1.20; 95% CI, 1.04-1.37) (Table 2).

Increased risk of prolonged opioid use was associated with use of antidepressants, opioids, benzodiazepines, alcohol, cocaine, or tobacco before surgery (Table 2). Preoperative use of opioids (OR, 5.32; 95% CI, 2.94-9.64), tobacco (OR, 1.55; 95% CI, 1.23-1.96), or cocaine (OR, 4.34; 95% CI, 1.50-12.58) were identified as having the strongest associations with prolonged use of opioids after surgery.

Medical comorbidities were differentiated into 3 specific categories: psychological, pain-associated conditions, and a broader category composed of disorders such as diabetes, pulmonary disease, and obesity (Table 2). When evaluating the association between psychological disorders...
| Source          | Country | Type of surgery | Data source or study setting | Participants, No. | Median age at baseline, y | Enrollment period | No. (%) | Participants with prolonged opioid use | Opioid-naive participants | Type of prolonged opioid use and definition | Follow-up time | NOWS score |
|-----------------|---------|-----------------|------------------------------|-------------------|--------------------------|------------------|---------|----------------------------------------|--------------------------|---------------------------------------------|-----------------|------------|
| Bateman et al, 16/2016 | US      | Cesarean delivery | Commercial insurance beneficiaries | 80 127 (100) | 285 (0.4) | Persistent use; using a trajectory model with 5 patient groups based on probability of an opioid fill during each of 12 consecutive 30-d follow-up; opioid fill in ≥4, 6, or 8 mo of follow-up | 1 y         | 9                                      |
| Raebal et al, 27/2014 | US      | Bariatric surgery | Commercial insurance beneficiaries | 10 643 (60.9) | 421 (4.0) | Chronic opioid use defined as ≥10 fills dispensing ≥90 consecutive days or ≥120-d total supply | 1 y         | 9                                      |
| Clarke et al, 46/2014 | Canada  | Major elective surgeries | National health care system databases | 39 140 (100) | 1229 (3.1) | Prolonged opioid use defined as the filling of opioid fills within the first 90 d after surgery and ≥1 opioid fill for 91-180 d after surgery | 6 mo        | 9                                      |
| Shah et al, 47/2017 | US      | Urologic surgery | Hospital institution data | 675 527 (62) | 608 (0.1) | Opioid dependence; outcome was assessed on the presence of ICD-9 diagnosis codes | 1 y         | 9                                      |
| Sun et al, 48/2017 | US      | Total knee arthroplasty, total hip arthroplasty, laparoscopic cholecystectomy, open cholecystectomy, laparoscopic appendectomy, open appendectomy, cesarean delivery, functional endoscopic sinus surgery, cataract surgery, transurethral prostate resection, and simple mastectomy | Commercial insurance beneficiaries | 641 941 (100) | 2039 (0.3) | Chronic opioid use defined as ≥10 opioid fills or ≤120-d supply of an opioid in the first 365 d after surgery, excluding the first 90 d after surgery | 1 y         | 9                                      |
| Connolly et al, 49/2017 | US      | Lumbar spinal fusion surgery | Commercial insurance beneficiaries | 8377 (49.6) | 2458 (29.3) | Long-term opioid use defined as opioid fill at least 365 d in 24 mo after surgery | 2 y         | 9                                      |
| Bedard et al, 50/2017 | US      | Total knee arthroplasty | Commercial insurance beneficiaries | 73 959 (NR) | 969 (3.2) | Prolonged opioid use defined as opioid fill each mo for up to 1 y after surgery | 1 y         | 9                                      |
| Johnson et al, 51/2016 | US      | Hand surgery | Commercial insurance beneficiaries | 59 725 (NR) | 7764 (13.0) | Prolonged opioid use defined as ≥1 opioid fill between 30 d before and 2 wk after surgery and ≥1 opioid prescription 90-180 d after surgery | 6 mo        | 9                                      |

(continued)
| Source                     | Country | Type of surgery                                                                 | Data source or study setting                      | Participants, No. | Median age at baseline, y | Enrollment period | Opioid-naive participants before surgery | Participants with prolonged opioid use | Opioid-naive participants | Type of prolonged opioid use and definition                                                                 | Follow-up time | NOWS score |
|----------------------------|---------|----------------------------------------------------------------------------------|--------------------------------------------------|-------------------|--------------------------|-------------------|-----------------------------------------|----------------------------------------|--------------------------|--------------------------------------------------------------------------------|------------------|-------------|
| Schoenfeld et al.          | US      | Spine surgery: discectomy, decompression, lumbar postero-lateral arthrodesis, or lumbar interbody arthrodesis | Military insurance beneficiaries, TRICARE         | 9991              | 46.4                     | January 1, 2006, to December 31, 2014 | 9991 (100) | 2 (0.02) | 2 (0.02) | Sustained opioid use defined as continued opioid use up to 6 mo after surgery | 1 y             | 9          |
| Westermann et al.          | US      | Rotator cuff repair                                                              | Commercial insurance beneficiaries               | 35155             | NR                       | January 1, 2007, to December 31, 2014 | 19925 (56.7) | 6749 (19.2) | 1594 (8.0) | Prolonged opioid use defined as opioid fill each mo up to 1 y after surgery | 3 mo             | 9          |
| Rosenbloom et al.          | Canada  | Traumatic musculoskeletal injury and corrective surgery                           | Hospital institution data                         | 122               | 44.8                     | May 2012 to July 2013                  | NR          | 43 (35.2) | NR                  | Persistent opioid use defined as ≥1 opioid fill 4 mo after surgery           | 4 mo             | 8          |
| Brummett et al.            | US      | Surgical procedure: major, ventral incisional hernia repair, colectomy, reflux surgery, bariatric surgery, and hysterectomy; minor, varicose vein removal, laparoscopic cholecystectomy, laparoscopic appendectomy, hemorroidectomy, thyroidectomy, transurethral prostate surgery, parathyroidectomy, and carpal tunnel | Commercial insurance beneficiaries               | 36177             | 44.6                     | January 1, 2012, to June 30, 2015       | 36177 (100) | 2176 (6.0) | 2176 (6.0) | Persistent opioid use defined as opioid fill 90-180 d after surgery          | 6 mo             | 9          |
| Fuzier et al.              | France  | Carpal tunnel surgery                                                            | National health care system                      | 3665              | 58                       | January 1 to June 30, 2010              | NR          | 183 (5.0) | NR                  | Prolonged opioid use defined as opioid fill each month from 2 mo before surgery to >2 to 12 mo after surgery | 1 y             | 9          |
| Carroll et al.             | US      | Mastectomy, lumpectomy, thoracotomy, and total hip or knee replacement             | Hospital institution data                         | 109               | NR                       | January 2007 to April 2009              | 21 (19.3)  | 6 (5.5)   | NR                  | Opioid use 150 d after surgery                                                    | 150 d            | 8          |
| Pugely et al.              | US      | Cervical spine surgery                                                           | Commercial insurance beneficiaries               | 17391             | NR                       | 2007-2015                              | 8278 (47.6) | 4128 (45.3) | 522 (6.3) | Prolonged opioid use defined as opioid prescription fill per month for 1 y after surgery | 1 y             | 9          |
| Politzer et al.            | US      | Total knee arthroplasty                                                          | Commercial insurance beneficiaries               | 66950             | NR                       | 2007-2013                              | 30282 (45.2) | 12760 (34.6) | 1514 (5.0) | Chronic opioid use defined as opioid fill for 6 contiguous months after surgery | 2 y             | 9          |

(continued)
| Source                  | Country | Type of surgery                                   | Data source or study setting | Participants, No. | Median age at baseline, y | Enrollment period | Opioid-naive participants before surgery | Opioid-naive participants with prolonged opioid use | Type of prolonged opioid use and definition                                                                 |
|------------------------|---------|---------------------------------------------------|-----------------------------|-------------------|--------------------------|-------------------|------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Swenson et al, 2018    | US      | Hysterectomy                                      | Commercial insurance beneficiaries | 24331             | NR                       | January 1, 2011 to December 31, 2014 | 24331 (100%) | 122 (0.5) | 122 (0.5) | Persistent opioid use defined as ≥2 opioid fills within 6 mo after surgery with ≥1 fill every mo and either total oral morphine equivalent of at least 1500 or at least 39 d of opioid supply | 6 mo | 8 |
| Namba et al, 2018      | US      | Total knee arthroplasty                           | Hospital institution data    | 23726             | 68                       | January 1, 2008, to September 30, 2011 | 14236 (40.0) | 7218 (30.4) | NR | Prolonged opioid use defined as number of opioid fills every 90-d period 1 yr after surgery | 1 y | 9 |
| Bennett et al, 2019    | US      | Body contouring surgical procedures after bariatric surgery | Commercial insurance beneficiaries | 11257            | 41.0                     | January 1, 2002, to September 30, 2014 | 11257 (100) | 690 (6.1) | 690 (6.1) | Persistent opioid use defined as continued opioid fills 90-180 d after surgery among patients who had opioid fills perioperatively | 6 mo | 8 |
| Westermann et al, 2019 | US      | Hip arthroscopy                                   | Commercial insurance beneficiaries | 1208             | NR                       | January 1, 2007, to June 30, 2016 | 698 (57.8) | 183 (15.1) | 37 (5.3) | Prolonged opioid use defined as opioid fills each mo up to 1 y after surgery | 1 y | 9 |
| Geesling et al, 2016   | US      | Total knee and total hip arthroplasty              | Hospital institution data    | 574               | 63.3                     | March 2010 to May 2013 | 407 (70.9) | 70 (12.2) | 20 (4.9) | Persistent opioid use defined as opioid fills at 6 mo after surgery | 6 mo | 7 |
| Lindestrand et al, 2015 | Denmark | Hip fracture surgery                             | Hospital institution data    | 413               | 79.5                     | May 30, 2010, to March 31, 2011 | 314 (76.0) | 124 (30.2) | 9 (2.9) | Persistent opioid use defined as opioid fills 90 and 180 d after surgery | 6 mo | 9 |
| Mulligan et al, 2016   | US      | Ankle and foot reconstruction                      | Hospital institution data    | 132               | 55                       | NR                      | 89 (67.4) | 52 (39.4) | 14 (15.7) | Defined as continued opioid use for 3 mo after surgery | 1 y | 8 |
| Rao et al, 2018        | US      | Shoulder arthroplasty                              | Hospital institution data    | 4243              | NR                       | January 1, 2008, to December 31, 2014 | 1061 (25.0) | 1598 (40.0) | NR | Persistent opioid use defined as opioid use after surgery within 1 y of surgery, evaluated quarterly | 1 y | 9 |
| Singh and Lewallen, 2010 | US      | Primary total hip arthroplasty                      | Hospital institution data    | 3005              | 64.9                     | 1993-2005 | NR | 85 (2.8) | NR | Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery | 2 and 5 y | 7 |
| Singh and Lewallen, 2012 | US      | Primary total knee arthroplasty                     | Hospital institution data    | 4234              | 68                       | 1993-2005 | NR | 61 (1.4) | NR | Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery | 2 and 5 y | 7 |
| Singh and Lewallen, 2014 | US      | Revision total knee arthroplasty                    | Hospital institution data    | 881               | 69                       | 1993-2005 | NR | 52 (5.9) | NR | Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery | 2 and 5 y | 7 |
| Valdes et al, 2015     | UK      | Total joint replacement                            | Hospital institution data    | 852               | 73.7                     | 2008-2014 | NR | 215 (25.1) | NR | Opioid use after surgery assessed by questionnaire given 1.27 y after index surgery | 4 y | 7 |

(continued)
Table 1. Characteristics of Included Studies (continued)

| Source | Country | Type of surgery | Data source or study setting | Participants, No. | Median age at baseline, y | Enrollment period | Opioid-naive participants before surgery | Participants with prolonged opioid use | Opioid-naive participants | Type of prolonged opioid use and definition | Follow-up time | NOWS score |
|--------|---------|-----------------|-------------------------------|-------------------|--------------------------|-----------------|------------------------------------------|--------------------------------------------|-------------------------------|---------------------------------------------|----------------|-----------|
| Rozet et al, 66 2014 | US | Knee arthroscopy | Military insurance beneficiaries, Veterans Affairs | 145 | 39 | 2007-2010 | 82 (56.6) | 43 (30.0) | NR | Prolonged opioid use defined as opioid fills uninterruptedly for >3 mo after surgery | 3.5 mo | 8 |
| Kim et al, 29 2017 | US | Hip or knee arthroplasty | Commercial insurance beneficiaries | 57545 | 61.5 | January 1, 2004, to December 31, 2013 | 7425 (12.9) | 4373 (7.6) | 48 (0.6) | Persistent opioid use defined as ≥1 opioid fill each mo during the 1 y after surgery based on group-based trajectory models | 1 y | 9 |
| Hansen et al, 67 2017 | Australia | Total knee arthroplasty | Military insurance beneficiaries, Australian Government Department of Veterans Affairs | 15020 | 79 | January 1, 2001, to December 31, 2012 | 9223 (61.4) | 787 (5.2) | 64 (0.7) | Chronic opioid use defined as >90 d of continuous opioid use or >120 d of cumulative use | 1 y | 9 |
| Inacio et al, 68 2016 | Australia | Total hip arthroplasty | Military insurance beneficiaries, Australian Government Department of Veterans Affairs | 9525 | 80 | January 1, 2001, to December 31, 2012 | 5138 (53.9) | 492 (5.2) | 38 (0.7) | Chronic opioid use defined as >90 d of continuous opioid use or >120-d cumulative use | 1 y | 9 |
| Hadlandsmyth et al, 69 2018 | US | Total knee arthroplasty | Military insurance beneficiaries, Veterans Affairs | 6653 | 66 | 2013-2015 | 5322 (80.0) | 866 (13.0) | 107 (2.0) | Chronic opioid use defined as continuous opioid fills assessed 3, 6, and 12 mo after surgery | 1 y | 8 |

Abbreviations: ICD, International Classification of Diseases; NOW, Newcastle-Ottawa Scale; NR, not reported.
before surgery and prolonged opioid use after surgery, increased risks were observed among participants with diagnoses of anxiety (OR, 1.14; 95% CI, 1.06-1.23), depression (OR, 1.54; 95% CI, 1.25-1.91), and mood disorders (OR, 1.85; 95% CI, 1.11-3.07). In contrast, patients with a diagnosis of bipolar disorder before surgery had significantly lower risks for prolonged opioid use after surgery (OR, 0.88; 95% CI, 0.79-0.98). Among pain conditions aggregated across all studies, prolonged opioid use after surgery was most strongly associated with a history of back pain (OR, 2.05; 95% CI, 1.63-2.58) and fibromyalgia (OR, 1.43; 95% CI, 1.15-1.79) (Table 2).

Sensitivity and Additional Analyses
Our primary findings remained largely unchanged in leave-one-out analyses (eTable 4 in the Supplement). No evidence of publication bias was found with the Egger regression-based test (intercept, -20.99; 95% CI, -46.04 to 4.07%; SE, 12.28; \( P = .10 \)) (eFigure in the Supplement). Studies involving only opioid-naive participants before surgery had lower pooled rates of prolonged opioid use after surgery (1.2%; 95% CI, 0.4%-3.9%). In the restricted analysis assessing chronic

---

**Figure 2. Forest Plot of Studies Assessing Prolonged Opioid Use After Surgery**

| Source                  | Event rate (95% CI) | Decreased rate of opioid use | Increased rate of opioid use |
|-------------------------|---------------------|------------------------------|------------------------------|
| Bateman et al,16 2016   | 0.004 (0.003-0.004) |                              |                              |
| Bedard et al,49 2017   | 0.119 (0.116-0.121) |                              |                              |
| Bennett et al,30 2019  | 0.061 (0.057-0.066) |                              |                              |
| Brummett et al,32 2017 | 0.060 (0.058-0.063) |                              |                              |
| Carroll et al,55 2012  | 0.055 (0.025-0.117) |                              |                              |
| Clarke et al,46 2014   | 0.031 (0.030-0.033) |                              |                              |
| Connolly et al,48 2017 | 0.293 (0.284-0.303) |                              |                              |
| Fuzier et al,34 2018   | 0.050 (0.043-0.057) |                              |                              |
| Goebling et al,56 2016 | 0.122 (0.098-0.151) |                              |                              |
| Hadlandmyth et al,55 2018 | 0.130 (0.127-0.138) |                              |                              |
| Hansen et al,62 2017   | 0.052 (0.049-0.056) |                              |                              |
| Incio et al,58 2016    | 0.052 (0.047-0.056) |                              |                              |
| Johnson et al,31 2016  | 0.130 (0.127-0.133) |                              |                              |
| Kim et al,29 2017      | 0.074 (0.072-0.076) |                              |                              |
| Lindestrand et al,59 2015 | 0.300 (0.258-0.346) |                              |                              |
| Mulligan et al,60 2016 | 0.394 (0.314-0.480) |                              |                              |
| Namba et al,33 2018    | 0.304 (0.298-0.310) |                              |                              |
| Politzer et al,57 2018 | 0.191 (0.188-0.194) |                              |                              |
| Pugely et al,36 2018   | 0.237 (0.231-0.244) |                              |                              |
| Raebel et al,23 2014   | 0.040 (0.036-0.043) |                              |                              |
| Rao et al,41 2018      | 0.377 (0.362-0.391) |                              |                              |
| Rosenbloum et al,51 2017 | 0.352 (0.273-0.441) |                              |                              |
| Rozet et al,56 2014    | 0.297 (0.228-0.376) |                              |                              |
| Schoenfeld et al,66 2017 | 0.000 (0.000-0.001) |                              |                              |
| Shah et al,67 2017     | 0.001 (0.001-0.001) |                              |                              |
| Singh and Lewallen,62 2010 | 0.028 (0.023-0.035) |                              |                              |
| Singh and Lewallen,63 2012 | 0.014 (0.011-0.018) |                              |                              |
| Singh and Lewallen,64 2014 | 0.059 (0.045-0.077) |                              |                              |
| Sun et al,11 2016      | 0.003 (0.003-0.003) |                              |                              |
| Swenson et al,32 2018  | 0.005 (0.004-0.006) |                              |                              |
| Valdes et al,65 2015   | 0.252 (0.224-0.283) |                              |                              |
| Westermann et al,51 2017 | 0.192 (0.188-0.196) |                              |                              |
| Westermann et al,52 2019 | 0.151 (0.132-0.173) |                              |                              |
| Total                   | 0.067 (0.045-0.098) |                              |                              |

Squares indicate event rates, with horizontal lines representing 95% CIs. The diamond represents the pooled total, with the points of the diamond representing 95% CIs. The data show substantial between-study heterogeneity (\( P < .001; I^2 = 99.96\% \)).
Table 2. Baseline Characteristics Associated With Prolonged Opioid Use After Surgery

| Characteristic                     | Studies, No. | References                                                                 | Random-effects pooled OR (95% CI) | I², % | P value |
|------------------------------------|--------------|----------------------------------------------------------------------------|-----------------------------------|-------|---------|
| **Demographic characteristic**    |              |                                                                            |                                   |       |         |
| Age                                |              |                                                                            |                                   |       |         |
| ≥50 y                              | NA           | NA                                                                         | 1 [Reference]                     | NA    | NA      |
| <50 y                              | 2            | 49, 56                                                                     | 1.83 (0.98-3.48)                  | 98.71 | <.001   |
| Body mass index*                   |              |                                                                            |                                   |       |         |
| <25                                | NA           | NA                                                                         | 1 [Reference]                     | NA    | NA      |
| 25-29.9                            | 4            | 62-64, 69                                                                  | 1.04 (0.52-2.10)                  | 41.63 | .16     |
| 30-34.9                            | 3            | 62-64                                                                      | 1.21 (0.61-2.38)                  | 38.58 | .20     |
| 35-39.9                            | 3            | 62-64                                                                      | 0.63 (0.31-1.30)                  | 0     | .54     |
| ≥40                                | 3            | 62-64                                                                      | 0.98 (0.42-2.33)                  | 17.52 | .26     |
| Sex                                |              |                                                                            |                                   |       |         |
| Male                               | NA           | NA                                                                         | 1 [Reference]                     | NA    | NA      |
| Female                             | 14           | 12, 31, 33, 46, 48, 49, 50, 52, 54, 56, 58, 61, 62, 65, 67, 69             | 1.16 (1.08-1.25)                  | 88.87 | <.001   |
| Race/ethnicity                     |              |                                                                            |                                   |       |         |
| White                              | NA           | NA                                                                         | 1 [Reference]                     | NA    | NA      |
| African American                   | 7            | 12, 27, 32, 33, 47, 61, 69                                               | 1.02 (0.92-1.13)                  | 69.35 | .01     |
| Asian                              | 4            | 12, 33, 47, 61                                                            | 0.68 (0.45-1.03)                  | 91.25 | <.001   |
| Hispanic                           | 5            | 12, 27, 33, 47, 61                                                         | 0.92 (0.80-1.05)                  | 79.85 | <.001   |
| Educational level                  |              |                                                                            |                                   |       |         |
| College degree or more             | NA           | NA                                                                         | 1 [Reference]                     | NA    | NA      |
| Less than high school              | 2            | 12, 30                                                                     | 1.06 (0.56-2.00)                  | 0     | .91     |
| High school                        | 2            | 12, 30                                                                     | 1.20 (1.04-1.37)                  | 0     | .63     |
| Some college                       | 2            | 12, 30                                                                     | 1.10 (0.92-1.33)                  | 49.41 | .16     |
| Preoperative medication use        |              |                                                                            |                                   |       |         |
| Antidepressants                    | 6            | 11, 16, 27, 29, 46, 69                                                    | 1.42 (1.11-1.81)                  | 90.97 | <.001   |
| Antipsychotics                     | 2            | 11, 16                                                                     | 1.15 (0.90-1.48)                  | 0     | .74     |
| Benzodiazepines                    | 5            | 11, 16, 29, 46, 69                                                        | 1.53 (1.20-1.95)                  | 91.72 | <.001   |
| Opioids                            | 14           | 12, 27, 29, 32, 33, 51, 52, 56, 58-61, 66, 69                             | 5.32 (2.94-9.64)                  | 99.57 | <.001   |
| Substance use                      |              |                                                                            |                                   |       |         |
| Alcohol                            | 8            | 11, 12, 29, 31, 47, 49, 53, 60                                            | 1.55 (1.07-2.25)                  | 90.74 | <.001   |
| Cocaine                            | 2            | 16, 29                                                                     | 4.34 (1.50-12.58)                 | 0     | .64     |
| Marijuana                          | 2            | 16, 29                                                                     | 0.89 (0.29-2.74)                  | 0     | .36     |
| Tobacco                            | 10           | 12, 16, 27, 29-31, 47-49, 60                                              | 1.55 (1.23-1.96)                  | 95.16 | <.001   |
| Medical comorbidities              |              |                                                                            |                                   |       |         |
| Mental health conditions           |              |                                                                            |                                   |       |         |
| Anxiety                            | 9            | 12, 27, 30, 33, 53, 53, 61-64                                             | 1.14 (1.06-1.23)                  | 61.10 | <.001   |
| Bipolar disorders                  | 2            | 33, 61                                                                     | 0.88 (0.79-0.98)                  | 0     | >.99    |
| Depression                         | 15           | 11, 32, 33, 47-49, 52, 53, 56, 61-64, 68, 71                             | 1.54 (1.25-1.91)                  | 97.90 | <.001   |
| Mood disorders                     | 3            | 12, 30, 60                                                                 | 1.85 (1.11-3.07)                  | 92.44 | <.001   |
| Psychiatric disorders              | 5            | 11, 30, 51, 61, 68                                                         | 1.04 (0.95-1.13)                  | 0     | .75     |
| Posttraumatic stress disorder      | 2            | 33, 61                                                                     | 1.39 (1.21-1.59)                  | 0     | .37     |
| Unspecified mental disorders       | 5            | 12, 30, 31, 33, 54                                                         | 1.45 (0.78-2.68)                  | 53.40 | .07     |

(continued)
opioid use,11,50,57,67-69 we observed a pooled rate of 2.3% (95% CI, 0.5%-10.6%). Similarly, in the 10 studies12,30,31,33,46,53,55,58,59,61 defining prolonged opioid use as the filling of at least 1 opioid prescription within the first 90 days after surgery and the filling of at least 1 additional opioid prescription from 91 to 180 days after surgery, the pooled rate was 13.8% (95% CI, 7.9%-23.0%). No significant difference was observed in a comparison of major vs minor surgical procedures (pooled rate, 7.0%; 95% CI, 4.9%-9.9% vs 11.1%; 95% CI, 6.0%-19.4%; \( P = .20 \)). Results from meta-analyses of other study-level factors are presented in Table 3.

### Discussion

This systematic review and meta-analysis of observational studies11,12,16,27,29-33,46-69 extend the results of a previous meta-analysis73 reporting prolonged opioid use among approximately 1 in 10 individuals undergoing a major or minor surgical procedure. Our analyses indicated that approximately 7% of patients filled opioid prescriptions at 3 months and more than 1 year after surgery, a time beyond the normal postoperative recovery period.74 A higher rate was observed when prolonged opioid use was defined as the filling of at least 1 prescription for opioids within 91 to 180 days after surgery. However, our primary pooled rate was attenuated when we restricted our analyses to patients considered as opioid naive before surgery or to studies involving a more conservative definition of prolonged use that is commonly used in the medical literature to characterize chronic opioid use. Although these rates may appear to be relatively low, the negative consequences that prolonged opioid use may impose on public health is perhaps better elucidated when indexed to the number of surgical procedures performed annually in the US. In 2010, approximately 51.4 million inpatient and 48.3 million ambulatory surgical procedures were estimated to have been performed in the US.75,76 Based on previous studies77 reporting that 4 of 5 patients undergoing surgery receive opioids, our pooled rate of 6.9%, when extrapolated to the total number of surgical procedures performed annually in the US, would represent millions of opioid prescriptions.
of surgical procedures, implies that up to 5.7 million Americans may potentially become persistent opioid users annually after surgery. Of note, individuals with prolonged opioid use after surgery constitute a group with potentially significant risk of chronic use. Therefore, prioritizing strategies that mitigate the transition of patients undergoing surgery to persistent opioid use while still optimizing the management of postoperative pain is of importance.

A possible approach to reducing the burden of prolonged opioid use is to characterize the underlying mechanisms, including patient-level risk factors, that may be associated with prolonged and/or chronic use of opioids after surgery. This approach, in part, rests on the assumption that patient-level risk factors associated with prolonged opioid use may be modifiable and can be used in screening for at-risk individuals. Our results indicate that preoperative exposure to medications, such as opioids, antidepressants, benzodiazepines, or cocaine; demographic factors, such as sex; and presence of medical comorbidities, including chronic pain, back pain, substance abuse, mood disorders, or depression before surgery, had some of the strongest associations with prolonged opioid use after surgery. Congruent with previous reviews, the strongest association in the current study was observed with preoperative opioid use, wherein individuals who had filled at least 1 opioid prescription in the year before surgery had a 5.3-fold risk of prolonged opioid use after surgery (pooled OR, 5.32; 95% CI, 2.94-9.64). These findings of increased risk of preoperative opioid use and prolonged use after surgery was further corroborated when we restricted our analyses to studies enrolling opioid-naive participants at baseline; the pooled rate of prolonged opioid use after surgery was 9.6 (6.2-14.6).

Table 3. Random-Effects Pooled Rates From Additional Analyses

| Characteristic                              | Studies, No. | Participants, No. | References | Pooled rate (95% CI) | P value | I², % | P value |
|--------------------------------------------|--------------|-------------------|------------|----------------------|---------|-------|---------|
| Country of patient enrollment             |              |                   |            |                      |         |       |         |
| US                                         | 26           | 1,854,006         | 12, 16, 27, 29-33, 47-52, 55-58, 60-64, 66, 69 | 5.8 (3.7-9.0) | .09 | 99.97 | <.001  |
| Non-US                                     | 7            | 68,737            | 46, 53, 54, 59, 65, 67, 68                      | 10.7 (6.2-18.1) | 99.56 | <.001 |
| Length of follow-up, mo                    |              |                   |            |                      |         |       |         |
| >6                                         | 22           | 1,715,595         | 11, 16, 16, 27, 29, 33, 47-50, 52, 54, 56, 57, 60-65, 67-69 | 5.4 (3.1-9.5) | .12 | 99.97 | <.001  |
| ≤6                                         | 11           | 207,148           | 12, 30-32, 46, 51, 53, 55, 58, 59, 66           | 9.6 (6.2-14.6) | .09 | 99.86 | <.001  |
| Source population or study setting         |              |                   |            |                      |         |       |         |
| Commercial insurance beneficiaries         | 14           | 1,124,786         | 11, 12, 16, 27, 29-32, 48, 49, 51, 52, 56, 57 | 6.0 (3.5-12.2) | NA | 99.97 | <.001  |
| Hospital institution data                  | 12           | 713,818           | 33, 47, 53, 55, 58, 59, 61-65, 72               | 9.8 (2.5-31.5) | .09 | 99.95 | <.001  |
| Military insurance beneficiaries           | 5            | 41,334            | 50, 66-69                                        | 5.4 (2.9-9.8) | .09 | 99.36 | <.001  |
| National insurance plans                   | 2            | 42,805            | 46, 54                                            | 3.9 (2.5-6.2) | .09 | 97.18 | <.001  |
| Major vs minor surgery                     |              |                   |            |                      |         |       |         |
| Major surgery                              | 27           | 1,228,350         | 16, 27, 29, 31-33, 46-51, 53, 55-65, 67-69      | 7.0 (4.9-9.9) | .20 | 99.94 | <.001  |
| Minor surgery                              | 4            | 16,275            | 30, 52, 54, 66                                    | 11.1 (6.0-19.4) | .09 | 98.75 | <.001  |
| Orthopedic vs nonorthopedic surgery        |              |                   |            |                      |         |       |         |
| Orthopedic                                 | 23           | 399,248           | 29, 31, 33, 48-54, 56-60, 62-69                   | 12.1 (7.7-14.9) | .07 | 99.84 | <.001  |
| Nonorthopedic                              | 6            | 806,128           | 16, 27, 30, 32, 47, 61                            | 1.7 (0.2-13.7) | NA | 99.97 | <.001  |
| Other study-level analyses                  |              |                   |            |                      |         |       |         |
| Only opioid-naive patients before surgery   | 8            | 902,689           | 11, 12, 30-32, 46, 50                             | 1.2 (0.4-3.9) | NA | 99.97 | <.001  |
| Similar definitions for chronic opioid use  | 7            | 760,723           | 11, 27, 50, 57, 67-69                             | 2.3 (0.5-1.6) | NA | 99.98 | <.001  |
| Similar definitions for prolonged opioid use after surgeryb | 10           | 175,486           | 12, 30, 31, 33, 46, 53, 55, 58, 59, 61           | 13.8 (7.9-23.0) | NA | 99.93 | <.001  |

Abbreviation: NA, not applicable.

a Included studies defining opioid use after surgery as the receipt of opioids for 10 opioid fills or more, 90 or more consecutive days' supply of opioids, or 120 cumulative days in the first year after surgery after excluding the first 90 postoperative days.

b Included studies defining prolonged opioid use as 1 opioid fill or more within 91 to 180 days after surgery.
surgery decreased more than 5-fold. Appropriate prescribing of the dose and quantity of opioids after surgery, the evaluation of opioid use in patients before surgery, and attempts to modify patient-level risk factors when possible or to treat underlying medical conditions before surgery may be included as part of a comprehensive strategy to reduce prolonged opioid use after surgery. Multimodal analgesia, psychobehavioral management of pain, and regional and neuraxial anesthesia have also been listed in the literature as strategies associated with reducing the transition to prolonged opioid use after surgery.

Although our analyses suggest that surgery may be associated with long-term opioid use, it is possible that the observed association was enhanced by confounding from an underlying chronic pain condition, the developing of persistent postsurgical pain, or surgical procedures exacerbating preexisting conditions and thus warranting long-term opioid management. Persistent postsurgical pain is a recognized complication of surgery and has been reported after common surgical procedures, including cesarean delivery or hip replacement. Several studies suggest that between 20% and 60% of individuals who undergo surgical procedures may transition from acute to persistent or chronic postsurgical pain. Because opioids were considered the standard of care for chronic noncancer pain management for studies included in this meta-analysis, the findings suggest that a high rate of prolonged opioid use after surgery may reflect the expected opioid use patterns among individuals with persistent postsurgical pain or underlying chronic pain. Because of a lack of information in the included studies, we were unable to assess the association between these confounding factors and opioid use after surgery in our analyses.

Of note, other mechanisms not associated with surgical pain before or after undergoing the procedure could have explained the findings of increased prolonged opioid use with surgery. Because major surgical procedures are likely to be associated with higher frequencies or intensities of postoperative pain and perhaps with a longer recovery time compared with minor surgical procedures, we expected significant differences in the pooled rate of prolonged opioid use in major vs minor surgical procedures. However, we found no such evidence in our subgroup analysis. Although a similar finding was recently reported in a large retrospective study of US adults undergoing minor or major surgical procedures, a meta-analysis by Mohamadi et al reported significant differences in prolonged opioid use between these categories of procedures. Therefore, further research should aim to delineate the causal mechanisms of continuous use of opioids in the postoperative period, particularly in the context of surgical pain.

Limitations
This study has limitations. Because the studies included in our analyses were observational by design, our findings may be prone to several forms of systematic bias, including selection bias and measurement errors. Of importance, our findings may have been subject to confounding by the underlying indication and inadequate bias adjustment. Second, although we performed several sensitivity analyses to explore the sources of heterogeneity, we were unable to explain the substantial heterogeneity present in most of our analyses. We used a random-effects model for our analyses, with the a priori assumption that the included studies would be heterogenous in their design, sample size, definitions of prolonged opioid use and risk factors, and adjustment of covariates. Third, because of a paucity of eligible studies and suboptimal reporting, we were unable to exclude studies involving participants with chronic opioid use at baseline, participants with preexisting pain disorders, or participants with a diagnosis of cancer before surgery—conditions that are frequently managed with opioids. Of note, the inclusion of these individuals may have led to an overestimation in the magnitude of prolonged opioid use after surgery. In addition, although less likely to be substantial, it is unknown the extent to which some of the eligibility criteria (eg, requiring studies to have reported the rate and risk factors for prolonged use) or not contacting authors may have affected the magnitude of observed association.

Despite these limitations, confidence in our findings is perhaps reinforced because of the absence of small-study bias and consistent results from study-level factors that might have
moderated our observed association. Nevertheless, further research is needed to quantify the effect of these various sources of bias on our study findings.

Conclusions

In this study, preoperative use of opioids and cocaine and the presence of comorbid pain conditions before surgery had the strongest associations with prolonged opioid use after surgery. These largely modifiable patient-level risk factors may be included as part of a comprehensive strategy to screen for at-risk individuals requiring transition to nonopioid interventions after surgery while ensuring appropriate short-term opioid use to manage postoperative pain. Research is needed to further investigate the association between surgical pain and prolonged opioid use after surgery.

ARTICLE INFORMATION

Accepted for Publication: April 3, 2020.
Published: June 25, 2020. doi:10.1001/jamanetworkopen.2020.7367

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Lawal OD et al. JAMA Network Open.

Corresponding Author: Xuerong Wen, PhD, MPH, MS, Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, 7 Greenhouse Rd, Ste 265F, Kingston, RI 02881 (xuerongwen@uri.edu).

Author Affiliations: Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston (Lawal, Gold, Murthy, Hume, Brothers, Wen); Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville (Ruchi); Pain Medicine Section, Anesthesiology Service, Malcom Randall VA Medical Center, Gainesville, Florida (Bavry); Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island (Hume); Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women and Infants Hospital of Rhode Island, Providence (Lewkowitz); Roger Williams Medical Center, Providence, Rhode Island (Brothers).

Author Contributions: Mr Lawal and Dr Wen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Lawal, Gold, Murthy, Wen.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Lawal, Gold, Lewkowitz, Wen.

Critical revision of the manuscript for important intellectual content: Lawal, Murthy, Ruchi, Bavry, Hume, Lewkowitz, Brothers, Wen.

Statistical analysis: Lawal, Gold, Wen.

Administrative, technical, or material support: Hume, Lewkowitz, Brothers, Wen.

Supervision: Lawal, Ruchi, Lewkowitz, Wen.

Conflict of Interest Disclosures: None reported.

Additional Contributions: Jacqueline Ewuoso, MPH, provided editorial assistance, and Mark Stuart Segal, MD, PhD, and Anthony Bavry, MD (Department of Medicine, University of Florida, Gainesville), provided support in the conduct of this project. These individuals were not financially compensated for their contributions.

REFERENCES

1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382. doi:10.15585/mmwr.mm6450a3

2. Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018;11:923-934. doi:10.2147/JPR.S160255

3. Centers for Disease Control and Prevention. Opioid overdose: understanding the epidemic. Updated March 19, 2020. Accessed July 22, 2019. https://www.cdc.gov/drugoverdose/epidemic/index.html
4. Alho H, Dematteis M, Lembo D, Maremmani I, Roncero C, Somaini L. Opioid-related deaths in Europe: strategies for a comprehensive approach to address a major public health concern. *Int J Drug Policy*. 2020;76:102616. doi: 10.1016/j.drugpo.2019.102616

5. Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. *Lancet*. 2016;387(10028):1644-1656. doi: 10.1016/S0140-6736(16)00161-6

6. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. *Med Care*. 2016;54(10):901-906. doi: 10.1097/MLR.0000000000002625

7. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? *Curr Drug Abuse Rev*. 2015;8(1):3-14. doi: 10.2174/187447370801150611184218

8. Chenaf C, Kaboré J-L, Delorme J, et al. Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. *Eur J Pain*. 2019;23(1):124-134. doi: 10.1016/j.ejp.1291

9. Rintoul AC, Dobbin MDH, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. *Inj Prev*. 2011;17(4):254-259. doi: 10.1136/injuryprev.2010.029611

10. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645. doi: 10.1001/jama.2016.1464

11. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. *JAMA Intern Med*. 2016;176(9):1286-1293. doi: 10.1001/jamainternmed.2016.3298

12. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. *JAMA Surg*. 2017;152(6):e170504. doi: 10.1001/jamasurg.2017.0504

13. Kehlet H, Jensen TS, Woof CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet*. 2006;367(9522):1618-1625. doi: 10.1016/S0140-6736(06)68700-X

14. Rawal N. Postoperative pain treatment for ambulatory surgery. *Best Pract Res Clin Anaesthesiol*. 2007;21(1):129-148. doi: 10.1016/j.bpa.2006.11.005

15. Ladha KS, Neuman MD, Broms G, et al. Opioid prescribing after surgery in the United States, Canada, and Sweden. *JAMA Netw Open*. 2019;2(9):e1910734. doi: 10.1001/jamanetworkopen.2019.10734

16. Bateman BT, Franklin JM, Bykov K, et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naive women. *Am J Obstet Gynecol*. 2016;215(3):353.e1-353.e18. doi: 10.1016/j.ajog.2016.03.016

17. Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. *Ann Surg*. 2017;265(4):709-714. doi: 10.1097/SLA.0000000000001993

18. Hernandez NM, Parry JA, Taunton MJ. Patients at risk: large opioid prescriptions after total knee arthroplasty. *J Arthroplasty*. 2017;32(8):2395-2398. doi: 10.1016/j.arth.2017.02.060

19. Bickel MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. *JAMA Surg*. 2017;152(11):1066-1071. doi: 10.1001/jamasurg.2017.0831

20. Caumo W, Schmidt AP, Schneider CN, et al. Preoperative predictors of moderate to intense acute postoperative pain in patients undergoing abdominal surgery. *Acta Anaesthesiol Scand*. 2002;46(10):1265-1271. doi: 10.1034/j.1399-6576.2002.461015.x

21. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. *Anesthesiology*. 2000;93(4):1123-1133. doi: 10.1097/00000542-200004000-00038

22. Katz J, Jackson M, Kavanagh BP, Sandler AN. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. *Clin J Pain*. 1996;12(1):50-55. doi: 10.1097/00002508-199603000-00009

23. Ip HYV, Abrishami A, Peng PWH, Wong J, Chung F. Predictors of postoperative pain and analgesic consumption: a qualitative systematic review. *Anesthesiology*. 2009;111(3):657-677. doi: 10.1097/ALN.0b013e3181ae87a

24. Sinatra R. Causes and consequences of inadequate management of acute pain. *Pain Med*. 2010;11(12):1859-1871. doi: 10.1111/j.1526-4637.2010.00983.x

25. Clarke H, Bonin RP, Orser BA, Englesakis M, Wijeysundera DN, Katz J. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. *Anesth Analg*. 2012;115(2):428-442. doi: 10.1213/ANE.0b013e318249d36e

26. Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: a retrospective cohort study. *Arch Intern Med*. 2012;172(5):425-430. doi: 10.1001/archinternmed.2011.1827
27. Raebel MA, Newcomer SR, Bayliss EA, et al. Chronic opioid use emerging after bariatric surgery. *Pharmacoepidemiol Drug Saf*. 2014;23(12):1247-1257. doi:10.1002/pds.3625

28. Hooten WM, St Sauver JL, McGree ME, Jacobson DJ, Warner DO. Incidence and risk factors for progression from short-term to episodic or longer-term opioid prescribing: a population-based study. *Mayo Clin Proc*. 2015;90(7):850-856. doi:10.1016/j.mayocp.2015.04.012

29. Kim SC, Choudhry N, Franklin JM, et al. Patterns and predictors of persistent opioid use following hip or knee arthroplasty. *Osteoarthritis Cartilage*. 2017;25(9):1399-1406. doi:10.1016/j.joca.2017.04.002

30. Bennett KG, Kelley BP, Vick AD, et al. Persistent opioid use and high-risk prescribing in body contouring patients. *Plast Reconstr Surg*. 2019;143(1):87-96. doi:10.1097/PRS.0000000000005084

31. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. *J Hand Surg Am*. 2016;41(10):947-957.e3. doi:10.1016/j.jhsa.2016.07.113

32. Swenson CW, Kamdar NS, Seiler K, Morgan DM, Lin P, As-Sanie S. Definition development and prevalence of new persistent opioid use following hysterectomy. *Am J Obstet Gynecol*. 2018;219(5):486.e1-486.e7. doi:10.1016/j.ajog.2018.06.010

33. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient factors associated with prolonged postoperative opioid use after total knee arthroplasty. *J Arthroplasty*. 2018;33(8):2449-2454. doi:10.1016/j.arth.2018.03.068

34. Bedard NA, DeMik DE, Dowdle SB, Callaghan JJ. Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty. *Bone Joint J*. 2018;100-B(1)(suppl A):62-67. doi:10.1302/0301-620X.100B1.BJJ-2017-0547.R1

35. Stroup DF, Berlin JA, Morton SC, et al; Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008

36. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700. doi:10.1136/bmj.b2700

37. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. *Clin J Pain*. 2008;24(6):521-527. doi:10.1097/AJP.0b013e3181869d03b

38. Macrae WA. Chronic post-surgical pain: 10 years on. *Br J Anaesth*. 2008;101(1):77-86. doi:10.1093/bja/aen099

39. Werner MJ, Kongsgaard UE, I. Defining persistent post-surgical pain: is an update required? *Br J Anaesth*. 2014;113(1):1-4. doi:10.1093/bja/aew012

40. International Association for the Study of Pain. IASP Task Force for the Classification of Chronic Pain in ICD-11 prepares new criteria on postsurgical and posttraumatic pain. Published February 9, 2016. Accessed July 24, 2019. https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=5134&navItemNumber=643

41. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed July 22, 2019.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

42. Egger M, Davey-Smith G, Altman D. *Systematic Reviews in Health Care: Meta-Analysis in Context*. 2nd ed. John Wiley & Sons; 2001. doi:10.1002/9780470693926

43. Cochran WG. The combination of estimates from different experiments. *Biometrics*. 1954;10(1):101-129. doi:10.2307/3001666

44. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558. doi:10.1002/sim.1186

45. Yeoh SL, Eastwood J, Wright IM, et al. Cognitive and motor outcomes of children with prenatal opioid exposure: a systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(7):e197025. doi:10.1001/jamanetworkopen.2019.7025

46. Clarke H, Soneji N, Ko DT, Yun L, Wijeysundera DN. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. *BMJ*. 2014;348:g2151. doi:10.1136/bmj.g2151

47. Shah AS, Blackwell RH, Kuo PC, Gupta GN. Rates and risk factors for opioid dependence and overdose after urological surgery. *J Urol*. 2017;198(5):1130-1136. doi:10.1016/j.juro.2017.05.037

48. Connolly J III, Javed Z, Raji MA, Chan W, Kuo Y-F, Baillargeon J. Predictors of long-term opioid use following lumbar fusion surgery. *Spine (Phila Pa 1976)*. 2017;42(18):1405-1411. doi:10.1097/BRS.0000000000002133
49. Bednar NA, Pugely AJ, Westermann RW, Duchman KR, Glass NA, Callaghan JJ. Opioid use after total knee arthroplasty: trends and risk factors for prolonged use. J Arthroplasty. 2017;32(8):2390-2394. doi:10.1016/j.arth.2017.03.014

50. Schoenfeld AJ, Nwosu K, Jiang W, et al. Risk factors for prolonged opioid use following spine surgery, and the association with surgical intensity, among opioid-naïve patients. J Bone Joint Surg Am. 2017;99(15):1247-1252. doi:10.2106/JBJS.16.01075

51. Westermann RW, Anthony CA, Bednar N, et al. Opioid consumption after rotator cuff repair. Arthroscopy. 2017;33(6):1467-1472. doi:10.1016/j.arthro.2017.03.016

52. Westermann RW, Mather RC III, Bednar NA, et al. Prescription opioid use before and after hip arthroscopy: a caution to prescribers. Arthroscopy. 2019;35(2):453-460. doi:10.1016/j.arthro.2018.08.056

53. Rosenblloom BN, McCartney CJL, Canzian S, Kreder HJ, Katz J. Predictors of prescription opioid use 4 months after traumatic musculoskeletal injury and corrective surgery: a prospective study. J Pain. 2017;18(8):956-963. doi:10.1016/j.jpain.2017.03.006

54. Fuzier R, Serres I, Bourrel R, Palmaro A, Lapeye-Mestre M. Analgesic drug prescription after carpal tunnel surgery: a pharmacoepidemiological study investigating postoperative pain. Reg Anesth Pain Med. 2018;43(1):19-24. doi:10.1097/AAP.0000000000000685

55. Carroll I, Barelka P, Wang CKM, et al. A pilot cohort study of the determinants of longitudinal opioid use after surgery. Anesth Analg. 2012;115(3):694-702. doi:10.1213/ANE.0b013e31825c049f

56. Pugely AJ, Bednar NA, Kalakoti P, et al. Opioid use following cervical spine surgery: trends and factors associated with long-term use. Spine J. 2018;18(11):1974-1981. doi:10.1016/j.spinee.2018.03.018

57. Politzer CS, Kildow BJ, Goltz DE, Bolognesi MP, Seyler TM. Trends in opioid utilization before and after total knee arthroplasty. J Arthroplasty. 2018;33(7(suppl)):S147-S153.e1. doi:10.1016/j.arth.2017.10.060

58. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and hip arthroplasty. Pain. 2016;157(6):1259-1265. doi:10.1097/j.pain.0000000000000516

59. Lindestrand AG, Christiansen MLS, Jantzen C, van der Mark S, Andersen SE. Opioids in hip fracture patients: an analysis of mortality and post hospital opioid use. Injury. 2015;46(7):1341-1345. doi:10.1016/j.injury.2015.04.016

60. Mulligan RP, McCarthy KJ, Grear BJ, Richardson DR, Ishikawa SN, Murphy GA. Psychosocial risk factors for postoperative pain in ankle and hindfoot reconstruction. Foot Ankle Int. 2016;37(10):1065-1070. doi:10.1177/1071100716655142

61. Rao AG, Chan PH, Prentice HA, et al. Risk factors for postoperative opioid use after elective shoulder arthroplasty. J Shoulder Elbow Surg. 2018;27(11):1960-1968. doi:10.1016/j.jse.2018.04.018

62. Singh JA, Lewallen D. Predictors of pain and use of pain medications following primary total hip arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years. BMC Musculoskelet Disord. 2010;11:90. doi:10.1186/1471-2474-11-90

63. Singh JA, Lewallen DG. Predictors of use of pain medications for persistent knee pain after primary total knee arthroplasty: a cohort study using an institutional joint registry. Arthritis Res Ther. 2012;14(6):R248. doi:10.1186/ar4091

64. Singh JA, Lewallen DG. Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty. Rheumatology (Oxford). 2014;53(10):1752-1758. doi:10.1093/rheumatology/ket443

65. Valdes AM, Warner SC, Harvey HL, et al. Use of prescription analgesic medication and pain catastrophizing after total joint replacement surgery. Semin Arthritis Rheum. 2015;45(2):150-155. doi:10.1016/j.semarthrit.2015.05.004

66. Rozet I, Nishio I, Robbertze R, Rotter D, Chansky H, Hernandez AV. Prolonged opioid use after knee arthroscopy in military veterans. Anesth Analg. 2014;119(2):454-459. doi:10.1213/ANE.0000000000000292

67. Hansen CA, Inacio MCS, Pratt NL, Roughhead EE, Graves SE. Chronic use of opioids before and after total knee arthroplasty: a retrospective cohort study. J Arthroplasty. 2017;32(3):811-817.e1. doi:10.1016/j.arth.2016.09.040

68. Inacio MCS, Hansen C, Pratt NL, Graves SE, Roughhead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open. 2016;6(4):e010664. doi:10.1136/bmjopen-2015-010664

69. Hadland Smith K, Vander Weg MW, McCoy KD, Mosher HJ, Vaughan-Sarrazin MS, Lund BC. Risk for prolonged opioid use following total knee arthroplasty in veterans. J Arthroplasty. 2018;33(1):119-123. doi:10.1016/j.arth.2017.08.022
70. Pang J, Tringale KR, Tapia VJ, et al. Chronic opioid use following surgery for oral cavity cancer. *JAMA Otolaryngol Head Neck Surg.* 2017;143(12):1187-1194. doi:10.1001/jamaoto.2017.0582

71. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. *JAMA.* 2013;310(13):1369-1376. doi:10.1001/jama.2013.278344

72. Mudumbai SC, Oliva EM, Lewis ET, et al. Time-to-cessation of postoperative opioids: a population-level analysis of the Veterans Affairs Health Care System. *Pain Med.* 2016;17(9):1732-1743. doi:10.1093/pm/pnw015

73. Mohamadi A, Chan JJ, Lian J, et al. Risk factors and pooled rate of prolonged opioid use following trauma or surgery: a systematic review and meta-(regression) analysis. *J Bone Joint Surg Am.* 2018;100(15):1332-1340. doi:10.2106/JBJS.17.01239

74. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain.* 2016;17(2):131-157. Published correction appears in *J Pain.* 2106;17(4):508-510. doi:10.1016/j.jpain.2015.12.008

75. National Quality Forum. Surgery 2015-2017 final report. Published April 2017. Accessed August 22, 2019. https://www.qualityforum.org/Publications/2017/04/Surgery_2015-2017_Final_Report.aspx

76. Hall MJ, Schwartzman A, Zhang J, Liu X. Ambulatory surgery data from hospitals and ambulatory surgery centers: United States, 2010. *Notl/Health Stat Report.* 2017;(102):1-15.

77. Wunsch H, Wijesundera DN, Passarella MA, Neuman MD. Opioids prescribed after low-risk surgical procedures in the United States, 2004-2012. *JAMA.* 2016;315(15):1654-1657. doi:10.1001/jama.2016.0130

78. Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. *Anesth Analg.* 2017;125(5):1733-1740. doi:10.1213/ANE.0000000000002458

79. Humble SR, Dalton AJ, Li L. A systematic review of therapeutic interventions to reduce acute and chronic postsurgical pain after amputation, thoracotomy or mastectomy. *Eur J Pain.* 2015;19(4):451-465. doi:10.1002/ejp.567

80. Richman JM, Liu SS, Courpas G, et al. Does continuous peripheral nerve block provide superior pain control to opioids? a meta-analysis. *Anesth Analg.* 2006;102(1):248-257. doi:10.1213/01.ANE.0000181289.09675.7D

81. Kehlet H, Rathmell JP. Persistent postsurgical pain: the path forward through better design of clinical studies. *Anesthesiology.* 2010;112(3):514-515. doi:10.1097/ALN.0b013e3181f8e422

82. Montes A, Roca G, Sabate S, et al; GENDOLCAT Study Group. Genetic and clinical factors associated with chronic postsurgical pain after hernia repair, hysterectomy, and thoracotomy: a two-year multicenter cohort study. *Anesthesiology.* 2015;122(5):1123-1141. doi:10.1097/ALN.0000000000000611

83. Richebé P, Capdevila X, Rivat C. Persistent postsurgical pain: pathophysiology and preventative pharmacologic considerations. *Anesthesiology.* 2018;129(3):590-607. doi:10.1097/ALN.0000000000002238

84. Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. *Expert Rev Neurother.* 2009;9(5):723-744. doi:10.1586/ern.09.20

85. Anderson JT, Haas AR, Percy R, Woods ST, Ahn UM, Ahn NU. Chronic opioid therapy after lumbar fusion surgery for degenerative disc disease in a workers’ compensation setting. *Spine (Phila Pa 1976).* 2015;40(22):1775-1784. doi:10.1097/BRS.0000000000001054

SUPPLEMENT.
eAppendix. Literature Search Strategy for MEDLINE
eTable 1. Included Studies Categorized by Definitions for Assessing Opioid Utilization After Surgery
eTable 2. Operational Definition of Opioid Naivety in Studies Enrolling Only Opioid-Naive Individuals Before Surgery
eTable 3. Classification of Surgeries into Minor, Major, or Major and Minor Surgeries
eTable 4. Risk Factors for Prolonged Opioid Use After Surgery (Pooled Estimates After Leave-1-Out Analyses)
eFigure 1. Funnel Plot Assessing Publication Bias/Small-Study Effects
eReferences.